640 filings
Page 24 of 32
8-K
1savmfc
7 Feb 11
Entry into a Material Definitive Agreement
12:00am
8-K
3s9g2zs
3 Feb 11
Ziopharm Announces Proposed Public Offering of Common Stock
12:00am
424B5
sbwqxwizlrh3jx9 ub8
2 Feb 11
Prospectus supplement for primary offering
12:00am
8-K
xfprv85jy4c 50ku6x2
26 Jan 11
ZIOPHARM Receives Positive Opinion for Orphan Drug Designation for Darinaparsin from European Medicines Agency
12:00am
D
hd4vr8px
14 Jan 11
$11.65M in equity / options, sold $11.65M, 1 investor
12:00am
8-K
8z1q 0ffkkgcy
12 Jan 11
ZIOPHARM Oncology and Intrexon Announce Worldwide Partnership for Synthetic Biology DNA-based Oncology Therapeutics
12:00am
8-K
47rk eewezzl4g5f4tu6
5 Jan 11
ZIOPHARM Oncology Announces First Patient Dosed in Phase I Study of
12:00am
8-K
pmswh57qai5rx1om1hcs
28 Dec 10
Departure of Directors or Certain Officers
12:00am
UPLOAD
ts0djalv1s adq
21 Dec 10
Letter from SEC
12:00am
CORRESP
e76d7v mqwe4vcmfrd
10 Dec 10
Correspondence with SEC
12:00am
UPLOAD
32olr929zjp gfnypjx
3 Dec 10
Letter from SEC
12:00am
8-K
ohgxc
12 Nov 10
Departure of Directors or Certain Officers
12:00am
8-K
yiu9du0pw wh9cutj8
4 Nov 10
Ziopharm Reports Third Quarter Financial Results
12:00am
CORRESP
dshikrxf7 zkyioiknb
15 Oct 10
Correspondence with SEC
12:00am
CORRESP
p4cgzzwkmrl9pdqj7pl
1 Oct 10
Correspondence with SEC
12:00am
8-K
wxkaxz wln5m
27 Sep 10
ZIOPHARM Granted Japanese Patent for Darinaparsin
12:00am
8-K
23ytkn f4jfjh
23 Sep 10
ZIOPHARM Receives FDA Orphan Drug Designation for Darinaparsin in the Treatment of Peripheral T-cell Lymphoma
12:00am
UPLOAD
ddwszjac0hlxe
20 Sep 10
Letter from SEC
12:00am
8-K
42hs2u
30 Jul 10
Changes in Registrant's Certifying Accountant
12:00am